| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 基础输液(元) | 253,474,124.76 | 680,664,345.50 | 414,546,403.90 |
| 医疗器械(元) | 50,773,812.54 | - | 62,950,939.34 |
| 治疗制剂(元) | 93,115,418.37 | 170,797,983.59 | 103,133,000.79 |
| 腹透液(元) | 217,731,967.46 | 348,122,524.90 | 178,126,326.09 |
| 其他(元) | 8,801,111.32 | 153,576,964.06 | 12,704,550.47 |
| 营业成本(元) | |||
| 基础输液(元) | 154,499,285.62 | 458,060,560.18 | 252,228,336.22 |
| 医疗器械(元) | 45,125,721.09 | - | 49,258,216.70 |
| 治疗制剂(元) | 48,043,142.35 | 88,470,949.95 | 48,836,091.99 |
| 腹透液(元) | 134,880,351.57 | 211,541,076.96 | 121,982,931.72 |
| 其他(元) | 5,932,627.96 | 118,754,812.18 | 7,891,927.09 |
| 毛利(元) | |||
| 基础输液(元) | 98,974,839.14 | 222,603,785.32 | 162,318,067.68 |
| 医疗器械(元) | 5,648,091.45 | - | 13,692,722.64 |
| 治疗制剂(元) | 45,072,276.02 | 82,327,033.64 | 54,296,908.80 |
| 腹透液(元) | 82,851,615.89 | 136,581,447.94 | 56,143,394.37 |
| 其他(元) | 2,868,483.36 | 34,822,151.88 | 4,812,623.38 |
| 毛利率(%) | |||
| 基础输液(%) | 39.05 | 32.70 | 39.16 |
| 医疗器械(%) | 11.12 | - | 21.75 |
| 治疗制剂(%) | 48.40 | 48.20 | 52.65 |
| 腹透液(%) | 38.05 | 39.23 | 31.52 |
| 其他(%) | 32.59 | 22.67 | 37.88 |
| 收入构成(%) | |||
| 基础输液(%) | 40.63 | 50.30 | 53.74 |
| 医疗器械(%) | 8.14 | - | 8.16 |
| 治疗制剂(%) | 14.92 | 12.62 | 13.37 |
| 腹透液(%) | 34.90 | 25.73 | 23.09 |
| 其他(%) | 1.41 | 11.35 | 1.65 |
| 毛利构成(%) | |||
| 基础输液(%) | 42.04 | 46.73 | 55.73 |
| 医疗器械(%) | 2.40 | - | 4.70 |
| 治疗制剂(%) | 19.15 | 17.28 | 18.64 |
| 腹透液(%) | 35.19 | 28.67 | 19.28 |
| 其他(%) | 1.22 | 7.31 | 1.65 |